Why Should You Choose ACPL for Compliance?
Why Should You Choose ACPL for Compliance? Choosing compliance is essential for businesses to operate legally, maintain credibility, and avoid penalties. Here are some key…
CDSCO vs. Other Regulatory Bodies: How It Compares to FDA & CE Marking
CDSCO vs. Other Regulatory Bodies: How It Compares to FDA & CE Marking When it comes to medical device and pharmaceutical regulations, different countries have
Latest CDSCO Guidelines for Drug Approval in India (2025 Update)
Latest CDSCO Guidelines for Drug Approval in India (2025 Update) The Central Drugs Standard Control Organization (CDSCO) is the apex regulatory authority for pharmaceuticals and
FSSAI Registration vs. FSSAI License: What’s the Difference?
FSSAI Registration vs. FSSAI License: What’s the Difference? If you are planning to start a food business in India, obtaining an FSSAI Registration or License
Why Your Food Business Needs an FSSAI License: Legal & Business Benefits
Why Your Food Business Needs an FSSAI License: Legal & Business Benefits If you own a food business in India, obtaining an FSSAI (Food Safety
Navigating the regulatory wave: How CDSCO’s oversight could transform India’s nutraceutical landscape
As India’s nutraceutical sector prepares for possible regulatory oversight by the CDSCO, Herbochem’s Karthik Kondepudi discusses how stricter, drug-style standards could reshape product development, quality assurance, consumer trust and global competitiveness.
FSSAI bans use of antibiotics in production of food animals — here’s what it means
The FSSAI’s 2024 amendment, effective 1 April 2025, prohibits antibiotics at every stage of producing milk, meat, poultry, eggs and aquaculture. It bans several antibiotic classes and specific drugs in food-animal production — a major step to curb antimicrobial residues in the food chain.
India mandates faster reporting of drug side effects
India’s drug regulator has sharply tightened its pharmacovigilance rules, requiring companies to report serious adverse drug effects within 15 days and other reactions within 90 days. Effective 1 February, the new DCGI guidance aims to strengthen oversight of the country’s pharmaceutical industry.